Santhera Pharmaceuticals clinical trials
The registry lists 29 studies whose lead sponsor is Santhera Pharmaceuticals or the company grouped under it. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Apr 23, 2026.
Our grouping of 2 registry names, not the registry’s. See them and correct one ↓
- 29studies on the registry
- 0open to participants now
What it is testing
The drugs Santhera Pharmaceuticals’ studies test, most studies first; none is open now — 5 drugs with a page of their own. Each count opens the studies in search.
Studies, none open
All 29 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 07
- 08
- 09
- 10
- 11
- 12
- 13
- 14
- 15
- 516
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started; 2 started before 2007. 2026 so far in the lighter column.
Registry sponsor names on this page
Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Santhera Pharmaceuticals.
- Santhera Pharmaceuticals27 studiesSame company
Something wrong?
- Juvantia Pharma Ltd2 studies →Acquired — became part of Santhera Pharmaceuticals, Oct 5, 2009 · source ↗
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 29 of 29.
- Expanded Access Protocol for Boys With Duchenne Muscular DystrophyAvailableNCT03863119
- A Study on Safety and Effectiveness of Long-term Treatment With Vamorolone in Boys With Duchenne Muscular DystrophyActive, not recruitingNCT06713135Phase 4
- Evaluation of Vamorolone CYP3A4 Induction on Midazolam (a Sensitive CYP 3A4 Substrate) PharmacokineticsCompletedNCT06689527Phase 1
- A Study to Assess Vamorolone in Boys Ages 2 to <4 Years and 7 to <18 Years With Duchenne Muscular Dystrophy (DMD)CompletedNCT05185622Phase 2
- Evaluation of Vamorolone Mineralocorticoid Receptor Antagonism in Healthy SubjectsCompletedNCT06649409Phase 1
- Study to Assess the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's AtaxiaCompletedNCT00537680Phase 3
- Study to Assess the Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia PatientsCompletedNCT00697073Phase 3
- Expanded Access Program for Idebenone in Patients With Leber's Hereditary Optic Neuropathy Who Completed the LEROS StudyNo longer availableNCT04381091
- Expanded Access Program for Idebenone in Participants With Duchenne Muscular Dystrophy (DMD)No longer availableNCT03433807
- Study to Assess the Efficacy and Safety of Raxone in LHON PatientsCompletedNCT02774005Phase 4
- A Phase III Double-blind Study With Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Taking Glucocorticoid SteroidsTerminatedNCT02814019Phase 3
- Phase III Study With Idebenone in Patients With Duchenne Muscular Dystrophy (SIDEROS-E)TerminatedNCT03603288Phase 3
- Clinical Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of POL6014 in Patients With CFCompletedNCT03748199Phase 1/2
- Congenital Muscular Dystrophy Ascending Multiple Dose Cohort Study Analyzing Pharmacokinetics at Three Dose Levels In Children and Adolescents With Assessment of Safety and Tolerability of Omigapil (CALLISTO)CompletedNCT01805024Phase 1
- Post Authorisation Safety Study With Raxone in LHON PatientsCompletedNCT02771379
- Historical Case Record Survey of Visual Acuity Data From Patients With Leber's Hereditary Optic Neuropathy (LHON)CompletedNCT02796274
- Long-Term Safety and Tolerability of Idebenone in Friedreich's Ataxia Patients (MICONOS Extension)CompletedNCT00993967Phase 3
- A Study to Assess the Potential for Pre-systemic Inhibition of CYP3A by Idebenone Using Midazolam as a SubstrateCompletedNCT02887443Phase 1
- A Study of Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia (FRDA) PatientsCompletedNCT00905268Phase 3
- Patient Reported Outcomes in Friedreich's Ataxia Patients After Withdrawal From Treatment With Idebenone (PROTI)CompletedNCT01303406Phase 3
- Phase III Study of Idebenone in Duchenne Muscular Dystrophy (DMD)CompletedNCT01027884Phase 3
- Study With Idebenone in Patients With Chronic Vision Loss Due to Leber's Hereditary Optic Neuropathy (LHON)WithdrawnNCT01495715Phase 3
- Leber Hereditary Optic Neuropathy (LHON) Historical Case Record SurveyCompletedNCT01892943
- RHODOS Follow-up Single-visit StudyCompletedNCT01421381
- Study to Assess Efficacy,Safety and Tolerability of Idebenone in the Treatment of Leber's Hereditary Optic NeuropathyCompletedNCT00747487Phase 2
- Efficacy and Tolerability of Idebenone in Boys With Cardiac Dysfunction Associated With Duchenne Muscular DystrophyCompletedNCT00654784Phase 2
- Long-term Safety, Tolerability and Efficacy of Idebenone in Duchenne Muscular Dystrophy (DELPHI Extension)CompletedNCT00758225Phase 2
- Safety and Efficacy Study of Fipamezole in Treatment of Motor Dysfunctions in Parkinson's DiseaseCompletedNCT00559871Phase 2
Sponsor listed in the registry: Juvantia Pharma Ltd · First submitted before Juvantia Pharma Ltd became part of Santhera Pharmaceuticals
- Fipamezole in Neurogenic Orthostatic HypotensionStatus unknownNCT00758849Phase 2
Sponsor listed in the registry: Juvantia Pharma Ltd · First submitted before Juvantia Pharma Ltd became part of Santhera Pharmaceuticals